Cerity Partners
SYRE icon

Cerity Partners’s Spyre Therapeutics SYRE Stock Holding History

Cerity Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-720
Closed -$125K – 724
2021
Q2 		$125K Buy
+720
New +$131K ﹤0.01% 691

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cerity Partners's SYRE Position: Q3 2021 in Review

Cerity Partners sold out of Spyre Therapeutics (SYRE) in Q3 2021, closing a stake of 720 shares — an estimated $125K sold.

Cerity Partners first reported a position in SYRE in Q2 2021 and held it in 1 quarter. The position peaked at $125K in Q2 2021. 77 funds tracked by Wall St. Rank hold SYRE as of Q3 2021.

  • Cerity Partners reported no remaining Spyre Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cerity Partners sold 720 Spyre Therapeutics shares in Q3 2021, an estimated $125K.
  • Cerity Partners first reported a position in Spyre Therapeutics in Q2 2021 and held it in 1 quarter.
  • Cerity Partners's Spyre Therapeutics position peaked at $125K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2021.

Based on Cerity Partners's 13F filing for Q3 2021, filed 25 Oct 2021.